Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

ClinicalTrials.gov ID: NCT00277498

Public ClinicalTrials.gov record NCT00277498. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 11:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Xalacom Given In The Evening, Xalatan Given In The Evening, And Timolol Given In The Morning In Patients With Open Angle Glaucoma Or Ocular Hypertension In The United States.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.

Study identification

NCT ID
NCT00277498
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
528 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2005 (Type not available)
Primary completion
Not listed
Completion
Jun 2007 (Actual)
Last update posted
Feb 18, 2021

2005 – 2007

United States locations

U.S. sites
64
U.S. states
27
U.S. cities
55
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35216 —
Pfizer Investigational Site Flagstaff Arizona 86001 —
Pfizer Investigational Site Artesia California 90701 —
Pfizer Investigational Site Los Angeles California 90048 —
Pfizer Investigational Site Newport Beach California 92663 —
Pfizer Investigational Site Sacramento California 95815 —
Pfizer Investigational Site San Francisco California 94105 —
Pfizer Investigational Site Colorado Springs Colorado 80907 —
Pfizer Investigational Site Gainesville Florida 32605 —
Pfizer Investigational Site Lecanto Florida 34461 —
Pfizer Investigational Site Miami Florida 33136 —
Pfizer Investigational Site Panama City Florida 32405 —
Pfizer Investigational Site Idaho Falls Idaho 83404 —
Pfizer Investigational Site Bourbonnais Illinois 60914 —
Pfizer Investigational Site Calumet City Illinois 60409 —
Pfizer Investigational Site Chicago Illinois 60611 —
Pfizer Investigational Site Chicago Illinois 60617 —
Pfizer Investigational Site Evansville Indiana 47713 —
Pfizer Investigational Site Madison Indiana 47250 —
Pfizer Investigational Site New Albany Indiana 47150 —
Pfizer Investigational Site Newburgh Indiana 47630 —
Pfizer Investigational Site Iowa City Iowa 52245 —
Pfizer Investigational Site Wichita Kansas 67208 —
Pfizer Investigational Site Louisville Kentucky 40217 —
Pfizer Investigational Site Bangor Maine 04401 —
Pfizer Investigational Site Reading Massachusetts 01867 —
Pfizer Investigational Site Ann Arbor Michigan 48105 —
Pfizer Investigational Site Detroit Michigan 48201-1423 —
Pfizer Investigational Site Stillwater Minnesota 55082 —
Pfizer Investigational Site Creve Coeur Missouri 63141-6846 —
Pfizer Investigational Site Kansas City Missouri 64114 —
Pfizer Investigational Site Warrensburg Missouri 64093 —
Pfizer Investigational Site Washington Missouri 63090 —
Pfizer Investigational Site Piscataway New Jersey 08854-4143 —
Pfizer Investigational Site Princeton New Jersey 08540-3211 —
Pfizer Investigational Site Brooklyn New York 11215 —
Pfizer Investigational Site New York New York 10032-3701 —
Pfizer Investigational Site Rochester New York 14618 —
Pfizer Investigational Site Durham North Carolina 27704-2122 —
Pfizer Investigational Site Durham North Carolina 27710 —
Pfizer Investigational Site Greensboro North Carolina 27408-7022 —
Pfizer Investigational Site Winston-Salem North Carolina 27101 —
Pfizer Investigational Site Cleveland Ohio 44115-3176 —
Pfizer Investigational Site Roseburg Oregon 97470 —
Pfizer Investigational Site Philadelphia Pennsylvania 19114 —
Pfizer Investigational Site Philadelphia Pennsylvania 19148 —
Pfizer Investigational Site Reading Pennsylvania 19606 —
Pfizer Investigational Site Wyomissing Pennsylvania 19610 —
Pfizer Investigational Site Charleston South Carolina 29403 —
Pfizer Investigational Site Charleston South Carolina 29414 —
Pfizer Investigational Site Maryville Tennessee 37803 —
Pfizer Investigational Site Austin Texas 78705 —
Pfizer Investigational Site Austin Texas 78746 —
Pfizer Investigational Site Dallas Texas 75231-5185 —
Pfizer Investigational Site El Paso Texas 79902 —
Pfizer Investigational Site El Paso Texas 79904 —
Pfizer Investigational Site Fort Worth Texas 76102-4427 —
Pfizer Investigational Site Houston Texas 77025-1635 —
Pfizer Investigational Site Houston Texas 77055 —
Pfizer Investigational Site San Antonio Texas 78205 —
Pfizer Investigational Site San Antonio Texas 78209 —
Pfizer Investigational Site San Antonio Texas 78240 —
Pfizer Investigational Site Fredericksburg Virginia 22405 —
Pfizer Investigational Site Seattle Washington 98133 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00277498, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 18, 2021 · Synced Oct 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00277498 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →